Establishment Labs (NASDAQ:ESTA) Shares Up 4.6% - Should You Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report)'s stock price rose 4.6% during mid-day trading on Monday . The company traded as high as $45.92 and last traded at $45.53. Approximately 106,487 shares changed hands during trading, a decline of 78% from the average daily volume of 474,794 shares. The stock had previously closed at $43.54.

Analyst Upgrades and Downgrades

ESTA has been the subject of a number of analyst reports. BTIG Research initiated coverage on Establishment Labs in a research report on Friday, May 16th. They set a "buy" rating and a $62.00 price objective for the company. Wall Street Zen upgraded Establishment Labs from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. Finally, Needham & Company LLC restated a "buy" rating and set a $48.00 price objective on shares of Establishment Labs in a research report on Friday, June 13th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $52.40.

Establishment Labs Stock Up 5.9%

The company has a current ratio of 3.36, a quick ratio of 2.05 and a debt-to-equity ratio of 5.72. The stock has a 50-day simple moving average of $37.11 and a 200-day simple moving average of $36.84. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -14.87 and a beta of 0.80.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The company had revenue of $41.38 million during the quarter, compared to analyst estimates of $41.15 million. During the same quarter in the previous year, the firm posted ($0.58) EPS. The firm's quarterly revenue was up 11.3% on a year-over-year basis. As a group, analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

A number of hedge funds and other institutional investors have recently modified their holdings of ESTA. Quarry LP acquired a new stake in shares of Establishment Labs during the fourth quarter worth $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Establishment Labs during the 1st quarter worth about $81,000. KLP Kapitalforvaltning AS bought a new stake in Establishment Labs during the 4th quarter valued at approximately $161,000. Elevation Point Wealth Partners LLC bought a new stake in Establishment Labs during the 1st quarter valued at approximately $207,000. Finally, Patriot Financial Group Insurance Agency LLC bought a new stake in Establishment Labs during the 1st quarter valued at approximately $234,000. Institutional investors own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.